Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas

R. Jakša, J. Karolová, M. Svatoň, D. Kazantsev, M. Grajciarová, E. Pokorná, Z. Tonar, M. Klánová, L. Winkowska, D. Maláriková, P. Vočková, K. Forsterová, N. Renešová, A. Dolníková, K. Nožičková, P. Dundr, E. Froňková, M. Trněný, P. Klener

. 2022 ; 102 (9) : 957-965. [pub] 20230104

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004939

Non-Hodgkin lymphomas (NHL) represent the most common hematologic malignancies. Patient-derived xenografts (PDXs) are used for various aspects of translational research including preclinical in vivo validation of experimental treatment approaches. While it was repeatedly demonstrated that PDXs keep majority of somatic mutations with the primary lymphoma samples, from which they were derived, the composition of PDX tumor microenvironment (TME) has not been extensively studied. We carried out a comparative genetic and histopathological study of 15 PDX models derived from patients with various types of NHL including diffuse large B-cell lymphoma (DLBCL; n = 7), Burkitt lymphoma (BL; n = 1), mantle cell lymphoma (MCL; n = 2), and peripheral T-cell lymphomas (PTCL; n = 5). Whole exome sequencing (WES) of the PDXs and primary lymphoma cells was implemented in 13 out of 15 cases with available DNA samples. Standard immunohistochemistry (IHC) was used to analyze the composition of PDX TME. WES data confirmed that PDXs maintained the genetic heterogeneity with the original primary lymphoma cells. In contrast, IHC analysis revealed the following recurrently observed alterations in the composition of PDX tumors: more blastoid lymphoma cell morphology, increased proliferation rate, lack of non-malignant cellular components including T cells and (human or murine) macrophages, and significantly lower intratumoral microvessel density and microvessel area composed of murine vessels. In addition, PDX tumors derived from T-NHL displayed additional differences compared to the primary lymphoma samples including markedly lower desmoplasia (i.e., the extent of both reticular and collagen fibrosis), loss of expression of cytotoxic granules (i.e., perforin, TIA, granzyme B), or loss of expression of T-cell specific antigens (i.e., CD3, CD4, CD8). Our data suggest that despite keeping the same genetic profiles, PDX models of aggressive NHL do not recapitulate the microenvironmental heterogeneity of the original lymphomas. These findings have implications on the relevance of PDX models in the context of preclinical research.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004939
003      
CZ-PrNML
005      
20250521101914.0
007      
ta
008      
230418s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41374-022-00784-w $2 doi
035    __
$a (PubMed)36775424
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Jakša, Radek $u Institute of Pathology, University General Hospital Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
245    10
$a Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas / $c R. Jakša, J. Karolová, M. Svatoň, D. Kazantsev, M. Grajciarová, E. Pokorná, Z. Tonar, M. Klánová, L. Winkowska, D. Maláriková, P. Vočková, K. Forsterová, N. Renešová, A. Dolníková, K. Nožičková, P. Dundr, E. Froňková, M. Trněný, P. Klener
520    9_
$a Non-Hodgkin lymphomas (NHL) represent the most common hematologic malignancies. Patient-derived xenografts (PDXs) are used for various aspects of translational research including preclinical in vivo validation of experimental treatment approaches. While it was repeatedly demonstrated that PDXs keep majority of somatic mutations with the primary lymphoma samples, from which they were derived, the composition of PDX tumor microenvironment (TME) has not been extensively studied. We carried out a comparative genetic and histopathological study of 15 PDX models derived from patients with various types of NHL including diffuse large B-cell lymphoma (DLBCL; n = 7), Burkitt lymphoma (BL; n = 1), mantle cell lymphoma (MCL; n = 2), and peripheral T-cell lymphomas (PTCL; n = 5). Whole exome sequencing (WES) of the PDXs and primary lymphoma cells was implemented in 13 out of 15 cases with available DNA samples. Standard immunohistochemistry (IHC) was used to analyze the composition of PDX TME. WES data confirmed that PDXs maintained the genetic heterogeneity with the original primary lymphoma cells. In contrast, IHC analysis revealed the following recurrently observed alterations in the composition of PDX tumors: more blastoid lymphoma cell morphology, increased proliferation rate, lack of non-malignant cellular components including T cells and (human or murine) macrophages, and significantly lower intratumoral microvessel density and microvessel area composed of murine vessels. In addition, PDX tumors derived from T-NHL displayed additional differences compared to the primary lymphoma samples including markedly lower desmoplasia (i.e., the extent of both reticular and collagen fibrosis), loss of expression of cytotoxic granules (i.e., perforin, TIA, granzyme B), or loss of expression of T-cell specific antigens (i.e., CD3, CD4, CD8). Our data suggest that despite keeping the same genetic profiles, PDX models of aggressive NHL do not recapitulate the microenvironmental heterogeneity of the original lymphomas. These findings have implications on the relevance of PDX models in the context of preclinical research.
650    _2
$a dospělí $7 D000328
650    _2
$a zvířata $7 D000818
650    _2
$a lidé $7 D006801
650    _2
$a myši $7 D051379
650    12
$a protinádorové látky $7 D000970
650    _2
$a imunohistochemie $7 D007150
650    12
$a difúzní velkobuněčný B-lymfom $x genetika $7 D016403
650    _2
$a nádorové mikroprostředí $x genetika $7 D059016
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Karolová, Jana $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic; First Department of Medicine- Hematology, University General Hospital Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Svatoň, Michael $u CLIP- Childhood Leukaemia Investigation Prague, Department of Pediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
700    1_
$a Kazantsev, Dmitry $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Grajciarová, Martina $u Department of Histology and Embryology and Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Pokorná, Eva $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Tonar, Zbyněk $u Department of Histology and Embryology and Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Klánová, Magdalena $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic; First Department of Medicine- Hematology, University General Hospital Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Winkowska, Lucie $u CLIP- Childhood Leukaemia Investigation Prague, Department of Pediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
700    1_
$a Maláriková, Diana $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic; First Department of Medicine- Hematology, University General Hospital Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic $7 xx0332458
700    1_
$a Vočková, Petra $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic; First Department of Medicine- Hematology, University General Hospital Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Forsterová, Kristina $u First Department of Medicine- Hematology, University General Hospital Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Renešová, Nicol $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Dolníková, Alexandra $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Nožičková, Kristýna $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Dundr, Pavel $u Institute of Pathology, University General Hospital Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Froňková, Eva $u CLIP- Childhood Leukaemia Investigation Prague, Department of Pediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
700    1_
$a Trněný, Marek $u First Department of Medicine- Hematology, University General Hospital Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Klener, Pavel $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic; First Department of Medicine- Hematology, University General Hospital Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: pavel.klener2@lf1.cuni.cz
773    0_
$w MED00003111 $t Laboratory investigation $x 1530-0307 $g Roč. 102, č. 9 (2022), s. 957-965
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36775424 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20250521101912 $b ABA008
999    __
$a ok $b bmc $g 1925188 $s 1191148
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 102 $c 9 $d 957-965 $e 20230104 $i 1530-0307 $m Laboratory investigation $n Lab Invest $x MED00003111
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace